January 2000
A Death in Philadelphia
An experimental gene-therapy treatment kills an eighteen-year-old volunteer in a clinical trial. Is this the final blow for a much-beleaguered technology?
By Stephen S. Hall
As many would-be biotech entrepreneurs have learned, one of the scariest things about bringing a new biomedical technology into the world is when an unexpected and very public problem crops up, especially during clinical trials. You can't tell if you've merely hit a bump in the road or run smack into a brick wall. At the moment of impact, they feel much the same.
![]() | Select from the choices above to read the entire article. |
Customer Service
|
Magazine Services
|
Subscribe
|
Other
|
Advertise
|


